Clinical outcomes of carbapenem therapy in OXA-48-producing Enterobacterales infections: a French multicentre cohort, systematic review, and meta-analysis.
Emerg Microbes InfectMay 19, 2026 (epub)
Laurent Dortet, Charlotte Moreau, Aurélien Dinh et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter cohort study and meta-analysis evaluated clinical outcomes of carbapenem therapy in patients with OXA-48-producing Enterobacterales infections. Among 59 patients in the French cohort, the 30-day mortality rate was 49.1%. The meta-analysis indicated that carbapenem therapy was linked to an increased risk of clinical failure compared to alternative therapies (OR = 2.02; 95% CI = 1.05-3.88).
Key findings
- 30-day mortality in the French cohort was 49.1%.
- 57.1% of patients on meropenem monotherapy experienced clinical failure.
- Carbapenem therapy had a crude mortality rate of 52% across 12 studies.
- Ceftazidime-avibactam showed lower crude mortality at 30.7%.
Why it matters
The findings highlight the potential ineffectiveness of carbapenem therapy for OXA-48-PE infections, despite in vitro susceptibility. Clinicians should consider alternative therapies to improve patient outcomes.